TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19370533
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy (2 cycles)
Study: 19370533
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy (3 cycles)
Study: 19370533
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy
Study: 16510768
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 250 mg twice daily
Study: 15585154
Drug: Absorption (AP)
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorption (AP) group
Study: 11214094
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine prophylaxis
Study: 11214094
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron and weekly folic-acid supplementation
Study: 29391265
Drug: G‐CSF group
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF group (n = 18)
Study: 29391265
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (G‐CSF + NAC) (n = 19)
Study: 29391265
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy group (n = 20)
Study: 26926657
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention (test 1 and test 2 groups)
Study: 20662342
Drug: Nutritional program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional program (NUT) - 10 mg/day iron, 11 mg zinc three times a week, 10000 IU/week of vitamin A
Study: 20662342
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH) - 1.26 IU/kg/day (0.042 mg/kg/day)
Study: 18166090
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (SRP + HMT + TAT)
Study: 16733739
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ferrous iron (fumarate)
Study: 16733739
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ferrous iron (fumarate)
Study: 16733739
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ferrous iron (fumarate)
Study: 16733739
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ferrous iron (fumarate)
Study: 16733739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ferritin >70 microg/l)
Study: 10586336
Drug: Fludarabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine alone (25 mg/m2/d x 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months)
Study: 8596381
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (400 microgram/day)
Study: 1947364
Drug: Cholinergic blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic blockade with 30 micrograms kg‐1 atropine administered by intravenous injection
Study: 6357772
Drug: progabide (+/-
Approvals — FDA: no, EMA: no, PMDA: no
Description: progabide (+/- 30 mg/kg/day)
Study: 31976819
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy home program (4 visits) during chemotherapy
Study: 31976819
Drug: General exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: General exercise during chemotherapy
Study: 26983164
Drug: Self-reported prescribing
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported prescribing of acetaminophen/paracetamol and opiates
Study: 25867579
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg daily for eight weeks)
Study: 20629136
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day istradefylline
Study: 17049679
Drug: NefTat and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NefTat and gp120(W61D) recombinant vaccine with AS02A adjuvant
Study: 16296364
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia with amino acid infusion
Study: 16296364
Drug: Sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anesthesia with amino acid infusion
Study: 11979398
Drug: Pramlintide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (25 microg/h or 50 microg/h) administered via 5-hour intravenous infusion
Study: 11979398
Drug: Pramlintide (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (30, 100, or 300 microg) administered via subcutaneous injections 3 times daily
Study: 11859
Drug: Cyclophosphamide (CY),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (CY), 50 mg/kg on each of 4 successive days
Study: 3571741
Drug: Self-control therapy
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control therapy
Study: 3571741
Drug: Behavioral problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral problem-solving therapy
Study: 21844075
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution and N-acetylcysteine (control group)
Study: 12706319
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acarbose t.i.d. for 6 weeks, followed by 100 mg acarbose t.i.d. for 12 weeks
Study: 1754607
Drug: Piracetam (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4.8 g daily for 6 weeks)
Study: 21970852
Drug: Erlotinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (oral antiepidermal growth factor receptor tyrosine kinase inhibitor)
Study: 19894376
Drug: Chinese decoction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese decoction, ligustrazin hydrochloride injection, and He‐Ne laser therapy
Study: 19894376
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and Vitamin C plus external application of 20% Azelaic acid cream
Study: 12719047
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (10 mL) and morphine 0.1% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% plus morphine 0.025% (5 mL/hr)
Study: 12719047
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (10 mL) and saline 0.9% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% (5 mL/hr)
Study: 9010708
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 4 days
Study: 1291405
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg p.o. omeprazole
Study: 1291405
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg i.v. omeprazole
Study: 1291405
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.v. omeprazole
Study: 6698373
Drug: Acetaminophen (2600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2600 mg orally 1 hour before aspirin or ethanol)
Study: 6698373
Drug: Aspirin (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1300 mg) or Ethanol (20% vol/vol)
Study: 6698373
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg orally 12 hours and 1 hour before acetaminophen)
Study: 19146517
Drug: Self-worth therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-worth therapy (30 minutes, once a week for 4 weeks)
Study: 19146517
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no therapy, 30 minutes of chatting once a week for 4 weeks)
Study: 19146517
Drug: Self-worth therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-worth therapy
Study: 10784481
Drug: 60 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/day of glycine added to clozapine
Study: 9075807
Drug: N(G)-monomethyl-L-arginine (NO-synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (NO-synthase inhibitor)
Study: 9075807
Drug: L-arginine (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (NO precursor)
Study: 3703632
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk supplemented with human milk protein (0.9 g/dL)
Study: 3703632
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk supplemented with medium-chain triglycerides (1 g/dL)
Study: 10907343
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group I)
Study: 10907343
Drug: Occlusive dressing
Normalized name: DSG Pak with Occlusive Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusive dressing therapy with bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group II)
Study: 8054072
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal application of nitroglycerin (15 hours/day)
Study: 8054072
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal application of nitroglycerin (24 hours/day)
Study: 770083
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg azapropazone per day
Study: 23599046
Drug: D-Cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine (50 mg before each of five exposure sessions)
Study: 20648212
Drug: Lumbar intraarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar intraarticular facet joint injections
Study: 20648212
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroids for conditions other than disc herniation or radiculitis
Study: 20648212
Drug: Sacroiliac joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacroiliac joint injections
Study: 18164457
Drug: Intradiscal electrothermal
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal electrothermal therapy
Study: 20648212
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy
Study: 20648212
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections in disc herniation or radiculitis
Study: 20648212
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injections in radiculitis
Study: 17901215
Drug: Physician communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician communication behaviors (interactive conversation, short-term goals, criteria for decision making, long-term treatment plan, tailoring according to needs)
Study: 10868720
Drug: Le Bon
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Le Bon Départ treatment
Study: 10868720
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration treatment
Study: 9106374
Drug: Nortriptyline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline for 6 weeks (with possible adjunctive lithium)
Study: 9106374
Drug: Phenelzine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine for 6 weeks (with possible lithium augmentation)
Study: 9106374
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy or fluoxetine for 6 weeks (with possible lithium augmentation)
Study: 3896663
Drug: Pivampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (500 mg or 1 g twice daily)
Study: 3896663
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg or 500 mg 3-times daily)
Study: 26919833
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) and Naoxintong Capsule (1.6 g thrice a day)
Study: 26919833
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (international normalized ratio 2.0-3.0)
Study: 26919833
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with NXT and warfarin
Study: 27511181
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment (titrated to trough levels of 5-10 ng/mL)
Study: 27511181
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment (for children who reached target trough levels)
Study: 24652518
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab treatment
Study: 31754133
Drug: β-blockers (metoprolol)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (metoprolol)
Study: 22972872
Drug: Pooled analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled analysis of β-blockers
Study: 10411846
Drug: Primary stenting
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary stenting with the heparin‐coated Palmaz‐Schatz stent
Study: 7738626
Drug: Dopamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2 micrograms/kg/min continuous infusion over 48 hours)
Study: 1876891
Drug: Lidocaine (LID)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg (Group A)
Study: 1876891
Drug: Lidocaine (LID)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg + Magnesium Sulfate (M) 2.5 mg/min (Group B)
Study: 29955932
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg daily)
Study: 25134291
Drug: GnRH analogues
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogues (subcutaneous triptorelin depot injection) before hydrothermal endometrial ablation (HTA)
Study: 25134291
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no presurgical treatment)
Study: 22481014
Drug: Curcuminoids 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids 4 g/day starting 3 days before surgery until 5 days after surgery
Study: 19859699
Drug: Placebo (sorbitol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sorbitol) tablets
Study: 19859699
Drug: Glucose tablets
Normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose tablets with other medication (NRT/bupropion)
Study: 19859699
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with other medication (NRT/bupropion)
Study: 19859699
Drug: Glucose tablets
Normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose tablets without other medication
Study: 19859699
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without other medication
Study: 16981901
Drug: Roflumilast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (500 microg once daily for 14 days)
Study: 16981901
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg oral and 1 mg i.v., 1 day apart)
Study: 7485932
Drug: Previous oral
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous oral herpes
Study: 369868
Drug: Paracetamol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1.0 g x 4 for 2 days, then 0.5 g x 4 for the next 2 days)
Study: 24051231
Drug: Theanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theanine (200 mg, twice a day, after breakfast and lunch)
Study: 22151785
Drug: Garlic (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (1200 μg allicin, three times daily)
Study: 22151785
Drug: d‐penicillamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐penicillamine (250 mg, three times daily)
Study: 11593322
Drug: Weekly CMV
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly CMV antigenemia testing with ganciclovir administration for a positive result
Study: 10186958
Drug: 2-minute treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-minute treatment of concentrated (5 mg/mL) albuterol in the Circulaire nebulizer
Study: 10186958
Drug: Conventional unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional unit dose treatment
Study: 8115670
Drug: Haloperidol (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10, 20 or 30 mg/day for three weeks)
Study: 3398512
Drug: Walking at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking at a pace that elicited 60% of V̇O2max, for 30 minutes, three times weekly for twelve weeks.
Study: 29411268
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with orange juice
Study: 29411268
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with water
Study: 29411268
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with omeprazole 20 mg and water
Study: 29411268
Drug: Omeprazole co-administration
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole co-administration
Study: 29411268
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (orange juice, water, omeprazole)
Study: 19244630
Drug: Droperidol 5
Normalized name: droPERidol 5 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5 mg IM
Study: 19244630
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg IM
Study: 12622339
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 0.65 g/kg alcohol and 4 mg/kg caffeine
Study: 12622339
Drug: 0.65 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g/kg alcohol alone
Study: 12622339
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg caffeine alone
Study: 8743003
Drug: 2% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide thrice daily
Study: 1889719
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg nightly (continuous dosing)
Study: 1889719
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg nightly (intermittent dosing)
Study: 1889719
Drug: Both intermittent
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intermittent and continuous dosing with ranitidine
Study: 6614662
Drug: Intravenous and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and/or oral potassium chloride supplementation during preoperative bowel preparation (60 mmol average supplementation)
Study: 31335755
Drug: Ketamine/propofol admixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine/propofol admixture (0.5 mg/kg of ketamine and propofol each)
Study: 1768820
Drug: Etomidate (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.15 mg/kg)
Study: 27179770
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (IV and topical TXA)
Study: 766619
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile saline solution)
Study: 22124602
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy focusing on strengthening exercises of the rotator cuff and scapula stabilizers (PT-group)
Study: 15223106
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate 2 mg per day plus normegestrol acetate 2.5 mg per day for 12 months
Study: 15223106
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 microg per day) plus normegestrol acetate 2.5 mg per day for 12 months
Study: 9679581
Drug: UFT as
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT as adjuvant chemotherapy for bladder cancer (12 patients)